ULTRAGENYX PHARMACEUTICAL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.24 USD | +0.89% |
|
+4.41% | -7.49% |
Chart calendar Ultragenyx Pharmaceutical Inc.
cca6259234c53.rKiBjPypRa38IRTBvxKBt6PLzt1q4RfrmqXsc9KhKsU.58fy_72aN92maljy7UrT2Pm8hOgFmHzbq-yEFKHCY_PuwcK0uvwp9M57IA~90ff107e6b4b23924aa1692ed9a976c2
Upcoming events on Ultragenyx Pharmaceutical Inc.
Past events on Ultragenyx Pharmaceutical Inc.
| 17/04/2024 13:00 | American Academy of Neurology Meeting |
| 17/04/2024 01:12 | American Academy of Neurology Meeting - Abstract #192 |
| 17/04/2024 00:30 | American Academy of Neurology Meeting - Poster (#8.002) |
| 17/04/2024 00:30 | American Academy of Neurology Meeting - Poster (#8.001) |
| 15/04/2024 13:00 | American Academy of Neurology Meeting |
| 13/03/2024 13:00 | Barclays Global Healthcare Conference |
| 12/03/2024 20:20 | Leerink Partners Global Biopharma Conference |
| 04/03/2024 14:10 | TD Cowen Health Care Conference |
| 15/02/2024 22:00 | Q4 2023 Earnings Call |
| 15/02/2024 21:01 | Q4 2023 Earnings Release |
| 08/01/2024 23:00 | JPMorgan Healthcare Conference |
| 29/11/2023 15:00 | Piper Sandler Healthcare Conference |
| 27/11/2023 | Evercore ISI HealthCONx Conference |
| 14/11/2023 12:30 | Jefferies London Healthcare Conference |
| 02/11/2023 21:00 | Q3 2023 Earnings Call |
| 02/11/2023 20:05 | Q3 2023 Earnings Release |
| 16/10/2023 13:30 | Analyst Day |
| 14/10/2023 21:30 | American Society For Bone And Mineral Research Conference - Presentation Number: SAT-500 |
| 14/10/2023 21:30 | American Society For Bone And Mineral Research Conference - Presentation Number: LB SAT-648 |
| 14/10/2023 21:30 | American Society for Bone and Mineral Research Meeting - Presentation Number: LB SAT-650 |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 104 103 1.03% | 271 250 8.4% | 351 352 -0.12% | 363 362 0.43% | 434 430 0.97% | 515 |
|
EBITDA Million USD | Released Forecast Spread | -416 -421 1.21% | -318 -287 -10.77% | -368 -343 -7.41% | -631 -608 -3.77% | -543 -549 1.02% | -504 |
|
EBIT Million USD | Released Forecast Spread | -424 -429 1.06% | -330 -303 -8.88% | -382 -369 -3.59% | -649 -640 -1.47% | -569 -563 -1.14% | -497 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -399 -382 -4.5% | -185 -237 21.65% | -453 -422 -7.29% | -702 -705 0.42% | -608 -616 1.21% | -534 |
|
Net income Million USD | Released Forecast Spread | -403 -385 -4.5% | -187 -238 21.48% | -454 -423 -7.23% | -707 -709 0.17% | -607 -617 1.65% | -532 |
|
EPS USD | Released Forecast Spread | -7,12 -6,84 -4.05% | -3,07 -3,88 20.87% | -6,70 -6,20 -8.12% | -10,1 -10,0 -0.82% | -8,25 -8,30 0.57% | -6,47 |
| Announcement Date | 13/02/20 | 11/02/21 | 10/02/22 | 16/02/23 | 15/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 83,4 83,7 -0.34% | 79,9 84,2 -5.12% | 89,3 87,3 2.3% | 90,7 95,7 -5.23% | 103 105 -1.68% | 100 104 -3.28% | 108 105 3.16% | 98,1 103 -4.69% | 127 121 5.29% | 117 | 126 | 130 | 143 | 129 |
|
EBITDA Million USD | Released Forecast Spread | -99,0 | -137 -114 -20.37% | -220 -106 -108.05% | -141 -97,3 -44.65% | -149 -117 -27.11% | -143 -131 -9.04% | -138 | -114 -96,2 -18.36% | ||||||
|
EBIT Million USD | Released Forecast Spread | -103 -95,0 -7.99% | -137 -116 -17.43% | -142 -117 -20.94% | -225 -155 -45.48% | -146 -139 -5.1% | -154 -135 -13.78% | -148 -142 -4.47% | -145 -142 -2.14% | -122 -121 -1.14% | -133 | -125 | -123 | -119 | -126 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -122 -95,9 -27.72% | -152 -116 -30.5% | -158 -116 -35.97% | -239 -164 -45.25% | -153 -146 -4.77% | -163 -140 -16.64% | -159 -149 -6.46% | -159 -153 -3.81% | -127 -130 2.58% | -138 | -131 | -128 | -120 | -132 |
|
Net income Million USD | Released Forecast Spread | -122 -93,1 -31.51% | -152 -120 -27.34% | -158 -121 -30.55% | -245 -163 -50.1% | -152 -145 -4.92% | -164 -139 -17.77% | -160 -151 -6.18% | -160 -152 -4.88% | -123 -134 8.35% | -140 | -131 | -129 | -124 | -132 |
|
EPS USD | Released Forecast Spread | -1,79 -1,35 -32.86% | -2,19 -1,78 -23.18% | -2,26 -1,77 -28.04% | -3,50 -1,84 -90.44% | -2,16 -2,18 0.74% | -2,33 -2,00 -16.65% | -2,25 -2,10 -7.21% | -2,23 -2,11 -5.52% | -1,52 -1,62 6.45% | -1,75 | -1,64 | -1,59 | -1,52 | -1,54 |
| Announcement Date | 10/02/22 | 05/05/22 | 28/07/22 | 02/11/22 | 16/02/23 | 04/05/23 | 03/08/23 | 02/11/23 | 15/02/24 | - | - | - | - | - |
More events
Past sector events for Ultragenyx Pharmaceutical Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- RARE Stock
- Calendar Ultragenyx Pharmaceutical Inc.
